CLOV vs BB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

CLOV

45.8
AI Score
VS
BB Wins

BB

51.5
AI Score

Investment Advisor Scores

CLOV

46score
Recommendation
HOLD

BB

52score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CLOV BB Winner
Revenue 2.25B 316.20M CLOV
Net Income 61.77M 42.40M CLOV
Net Margin 2.7% 13.4% BB
Operating Income 61.77M 48.90M CLOV
ROE 15.8% 5.4% CLOV
ROA 8.2% 3.4% CLOV
Total Assets 753.68M 1.26B BB
Current Ratio 1.55 2.38 BB
Free Cash Flow 201.03M 29.80M CLOV

Relative Price Performance (Last 90 Days)

CLOV 1M: +4.1% · 3M: +11.5% BB 1M: +13.6% · 3M: +7.0%

Current Technical Phase

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.9% over 20 days), RSI 60

RSI (14): 60.5 · Price: $5.01

BB

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 59

RSI (14): 58.5 · Price: $9.62

Fundamentals Snapshot

Metric CLOV BB
Market Cap — —
Forward P/E 27.4 55.6
Trailing P/E 483.0 70.9
Revenue (TTM) — —
Revenue Growth 0.5% 0.3%
Gross Margin 0.2% 0.8%
Operating Margin 0.0% 0.2%
EPS 0.01 0.13
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BB is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.